Zacks Investment Research upgraded shares of Uniqure (NASDAQ:QURE) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Zacks Investment Research currently has $33.00 price objective on the biotechnology company’s stock.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
Other analysts have also issued research reports about the stock. HC Wainwright set a $42.00 target price on shares of Uniqure and gave the company a buy rating in a research report on Tuesday, July 17th. B. Riley initiated coverage on shares of Uniqure in a research report on Wednesday, June 27th. They issued a buy rating and a $50.00 target price on the stock. Cantor Fitzgerald set a $58.00 target price on shares of Uniqure and gave the company a buy rating in a research report on Thursday, August 23rd. Cowen reiterated a buy rating on shares of Uniqure in a research report on Monday, August 13th. Finally, Janney Montgomery Scott reiterated a buy rating on shares of Uniqure in a research report on Wednesday, August 8th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $44.33.
Shares of NASDAQ QURE traded up $0.69 during trading on Wednesday, hitting $28.53. The company had a trading volume of 331,891 shares, compared to its average volume of 349,171. Uniqure has a fifty-two week low of $9.47 and a fifty-two week high of $43.23. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -9.70 and a beta of 0.27. The company has a quick ratio of 8.36, a current ratio of 8.36 and a debt-to-equity ratio of 0.06.
Uniqure (NASDAQ:QURE) last announced its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.04. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.37 million. Equities research analysts anticipate that Uniqure will post -2.44 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of QURE. Quantbot Technologies LP boosted its position in Uniqure by 3,972.6% during the first quarter. Quantbot Technologies LP now owns 5,498 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 5,363 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in Uniqure by 276.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 4,700 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new position in Uniqure during the first quarter worth about $177,000. Gagnon Securities LLC acquired a new position in Uniqure during the second quarter worth about $209,000. Finally, Jane Street Group LLC acquired a new position in Uniqure during the first quarter worth about $224,000. Hedge funds and other institutional investors own 59.32% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Recommended Story: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.